Pharmacokinetics of Afrezza

Afrezza (insulin human) inhalation powder is a rapid-acting insulin delivered directly to the pulmonary alveoli via a small, breath-powered inhaler. Unlike subcutaneous insulins, which must be absorbed from the interstitial space, Afrezza passes quickly through the alveolar‑capillary membrane. This unique route of administration yields a pharmacokinetic profile that closely mimics the natural first‑phase insulin secretion seen in healthy individuals after carbohydrate ingestion. The inhaled particles are dry powder liposomes containing recombinant human insulin, engineered to release the hormone almost instantaneously upon reaching the moist environment of the deep lung.

The key pharmacokinetic parameters of Afrezza are defined by its rapid absorption, short time to peak concentration (Tmax), and brief duration of action. After a single inhalation, insulin appears in the bloodstream within 10–15 minutes. Peak serum insulin concentrations are reached at approximately 53 minutes (range 12–180 minutes), and the effect declines to baseline by about 2.5–3 hours. This profile contrasts sharply with subcutaneous rapid-acting analogs such as insulin lispro or insulin aspart, which typically have an onset of 15–30 minutes, a peak at 1–2 hours, and a duration of 3–5 hours. For Afrezza, the area under the insulin concentration‑time curve (AUC) varies linearly with the inhaled dose across the clinically relevant range (4–48 units), indicating predictable systemic exposure.

Absorption and Bioavailability

Pulmonary absorption of Afrezza is rapid because of the very large surface area of the alveoli, the thinness of the alveolar‑capillary membrane, and the rich blood supply of the lung. The absolute bioavailability of Afrezza is approximately 27% relative to an equivalent dose of subcutaneously injected regular insulin. However, this value can be influenced by the patient’s inspiratory flow rate. The inhaler is designed to deliver a consistent dose when the user takes a forceful, deep breath. In clinical trials, peak inspiratory flow (PIF) rates of 40–60 L/min produced reproducible drug deposition, while slower or weaker inhalations reduced both the rate and extent of absorption. Manufacturers therefore instruct patients to perform a full exhalation, seal their lips around the mouthpiece, and inhale as quickly and deeply as possible, followed by a 5‑second breath‑hold.

Food intake immediately before or after inhalation does not appear to significantly alter the total absorption of Afrezza, but the timing of inhalation in relation to meal ingestion is critical for glycemic efficacy. Because the onset of action is faster than that of injectable prandial insulins, patients must inhale Afrezza at the start of the meal—or even up to five minutes after beginning to eat—rather than 15–30 minutes before, as is recommended for some older regular insulins. This convenience helps reduce pre‑meal dosing anxiety and simplifies mealtime planning.

Distribution

Once in the bloodstream, Afrezza’s distribution is identical to that of endogenous insulin. It is widely distributed throughout the extracellular fluid, with a volume of distribution of approximately 0.2–0.4 L/kg. About 20–30% of circulating insulin is bound to plasma proteins, primarily albumin. The lung itself does not act as a significant depot; any insulin not absorbed is cleared by pulmonary macrophages or mucociliary transport and subsequently degraded or swallowed. The rapid clearance from the pulmonary compartment ensures that the insulin effect is driven entirely by the circulating drug rather than by a prolonged reservoir effect.

Metabolism and Elimination

Afrezza is metabolized by the same enzymatic pathways that degrade endogenous insulin. In humans, the primary site of insulin catabolism is the liver, where the hormone is cleaved by insulin‑degrading enzyme (IDE) and then excreted into bile. The kidneys also play a major role, filtering free insulin in the glomerulus and reabsorbing and degrading much of it in proximal tubular cells. The total body clearance of Afrezza is similar to that of subcutaneous regular insulin, approximately 600–800 mL/min. The terminal half‑life is about 1.2 hours—substantially shorter than the half‑life of subcutaneous rapid‑acting insulins (3–5 hours). This short half‑life is a direct consequence of rapid absorption combined with efficient systemic clearance, and it underlies the drug’s brief pharmacodynamic effect.

Because Afrezza is a protein, it is not subject to cytochrome P450–based drug–drug interactions. However, any condition that alters hepatic or renal blood flow—such as advanced cirrhosis or end‑stage renal disease—could theoretically affect insulin clearance, although no dedicated studies have been performed in these populations. In patients with severe renal impairment, caution is warranted because reduced metabolic clearance may prolong the duration of Afrezza’s glucose‑lowering action, potentially increasing the risk of late‑post‑meal hypoglycemia.

Impact on Blood Glucose Levels

The distinct pharmacokinetics of Afrezza translate directly into a unique pharmacodynamic profile: a rapid onset of glucose‑lowering action, a pronounced peak effect that coincides with the postprandial glucose excursion, and a quick return to near‑baseline activity within 2–3 hours. This pattern allows Afrezza to specifically target the glucose surge that occurs 30–90 minutes after a meal, known as postprandial hyperglycemia. Clinical studies have consistently demonstrated that Afrezza reduces 2‑hour postprandial glucose excursions by 2.5–5.5 mmol/L (45–100 mg/dL), depending on the dose and the carbohydrate content of the meal.

Postprandial Glucose Control

The most important clinical impact of Afrezza’s rapid action is its ability to blunt the post‑meal glucose peak. In a study published in Diabetes Care (2015), patients with type 1 diabetes who used Afrezza with meals achieved a mean 2‑hour postprandial glucose level of 8.0 mmol/L (144 mg/dL), compared with 9.7 mmol/L (174 mg/dL) for patients using subcutaneous insulin aspart. The reduction in glucose excursion was most pronounced during the first two hours after inhalation, after which both groups converged. Similar benefits have been observed in type 2 diabetes, where Afrezza added to basal insulin significantly lowered fasting and postprandial glucose without increasing weight gain.

Hypoglycemia Risk and Timing

One of the major advantages of Afrezza is its low risk of inter‑meal hypoglycemia. Because the insulin activity returns to baseline within 3 hours, there is little residual effect to cause a late‑onset hypoglycemic event. In the same Diabetes Care trial, the incidence of nocturnal hypoglycemia was significantly lower with Afrezza (2.1 events per patient‑year) than with insulin aspart (5.3 events per patient‑year). However, early postprandial hypoglycemia—within the first 2 hours after a meal—can occur if the dose is too high relative to the meal’s carbohydrate content or if the patient delays eating after inhaling. Because Afrezza’s effect peaks around 53 minutes, a mismatch between insulin action and carbohydrate absorption can produce a rapid drop in glucose. Therefore, careful carbohydrate counting and dose adjustment are essential.

Patients who use intensive insulin therapy with multiple daily injections (MDI) or insulin pumps often struggle with late‑onset hypoglycemia from the “tail” of basal or rapid‑acting analogs. Afrezza’s short duration circumvents this problem entirely, making it a particularly attractive option for individuals with unpredictable meal schedules, those who engage in postprandial exercise, or those who have recurrent late‑post‑meal hypoglycemia. Clinical guidelines from the American Diabetes Association now recognize inhaled insulin as a viable alternative for mealtime coverage, especially in patients who prefer a needle‑free option or who experience injection‑related lipohypertrophy.

Comparative Efficacy with Other Prandial Insulins

Head‑to‑head trials have compared Afrezza with insulin lispro, aspart, and regular human insulin. In type 1 diabetes, Afrezza provided comparable overall glycemic control (measured by HbA1c reduction) to subcutaneous rapid‑acting analogs, with a small but statistically significant increase in fasting glucose (about 0.3–0.5 mmol/L) that may be attributable to the lack of basal residual effect. However, given that Afrezza is intended only for prandial coverage, patients must always use a background basal insulin. In type 2 diabetes, where endogenous insulin secretion may still be present, Afrezza alone—or combined with oral agents—has been shown to lower HbA1c by 0.4–0.8% over 24 weeks, similar to changes seen with mealtime subcutaneous insulin.

It is worth noting that the pharmacokinetic variability of Afrezza is somewhat higher than that of subcutaneous insulins, primarily because of differences in lung function, PIF, and deposition patterns from dose to dose. Nevertheless, the coefficient of variation for Afrezza’s glucose‑lowering effect (measured by glucose infusion rate in euglycemic clamp studies) is approximately 30–40%, which is comparable to the variability observed with subcutaneous insulin analogs in real‑world settings.

Clinical Considerations for Optimal Use

To maximize the benefits of Afrezza while minimizing risks, healthcare providers must carefully select patients, provide thorough instruction on inhalation technique, and ensure appropriate monitoring.

Patient Selection and Contraindications

Afrezza is contraindicated in patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD), asthma, or pulmonary fibrosis, because of an increased risk of bronchospasm. Spirometry (FEV1) must be performed before initiation, after 6 months of therapy, and annually thereafter. If a patient’s FEV1 decreases by ≥20% relative to baseline, Afrezza should be discontinued. Smokers and recent quitters (within the past 6 months) are also excluded because smoking alters lung permeability and insulin absorption unpredictably. For patients with well‑controlled asthma who are not using inhaled corticosteroids, Afrezza is not recommended. Pregnant women with diabetes were not included in pivotal trials, so the drug is classified as pregnancy category C; use only if clearly needed.

Ideal candidates for Afrezza are non‑smoking adults with type 1 or type 2 diabetes who have normal lung function and who seek a needle‑free alternative. The drug is particularly useful for individuals who experience anxiety about injections, those who have lipodytrophy that interferes with injection‑site rotation, and those with an erratic daily routine that makes pre‑meal insulin timing difficult. Children under 18 years of age have not been studied, and Afrezza is not approved for pediatric use.

Inhalation Technique and Dose Titration

Proper inhalation technique is arguably the most critical factor for consistent pharmacokinetics. Patients should be instructed to: (1) exhale completely away from the inhaler; (2) place the mouthpiece in the mouth and seal the lips tightly; (3) inhale forcefully and deeply; (4) hold their breath for 5 seconds; and (5) exhale away from the inhaler. The device emits one cartridge per dose, and each cartridge contains 4, 8, or 12 units of insulin. The dose is selected by inserting the appropriate cartridge. Dosing should be titrated based on glucose self‑monitoring, with a starting dose of 4 units for patients with type 1 diabetes or 4–8 units for type 2 diabetes, adjusted to achieve target 2‑hour postprandial levels.

Because Afrezza is less potent than subcutaneous insulin on a unit‑unit basis (bioavailability ~27%), the labeled “units” refer to the amount of drug that yields an approximate pharmacodynamic equivalency to 1 unit of subcutaneous insulin. In practice, many patients require a slightly higher inhaled dose than their previous subcutaneous prandial dose. A conversion algorithm suggested by the manufacturer: for those on injectable rapid‑acting insulin, start with the same number of units of Afrezza; for those on regular insulin, reduce the dose by 20%. Frequent follow‑up every 2–3 days during initial titration is recommended to fine‑tune the dose and to educate about recognizing early postprandial hypoglycemia.

Monitoring and Adverse Effects

Self‑monitoring of blood glucose (SMBG) is essential, especially during the initial weeks and after dose adjustments. Patients should check glucose immediately before meals, 2 hours after meals, and before bed. The most common adverse effect is cough (occurring in up to 15–25% of patients, usually mild and transient). Other pulmonary events include throat pain and dysphoria (unpleasant taste). Serious but rare adverse events include acute bronchospasm and decline in pulmonary function. As per FDA recommendations, a baseline measurement of FEV1 should be documented, and lung function testing should be repeated at 6 months and yearly. If FEV1 declines by ≥20%, the drug must be discontinued.

Of note, Afrezza’s rapid action means that hypoglycemia can occur very quickly after a meal if the dose is excessive. Patients should keep fast‑acting glucose sources (e.g., glucose tablets, juice) readily available, and they should be educated about the symptoms and treatment of hypoglycemia. Since the window of action is short, repeating treatment for hypoglycemia may be unnecessary if the glucose source provides sustained counter‑regulation; nonetheless, it is prudent to re‑check glucose after 15 minutes.

Conclusion

Afrezza’s unique pharmacokinetic profile—rapid pulmonary absorption, short time to peak concentration, and brief 2–3 hour duration of action—offers a novel tool for managing postprandial hyperglycemia in diabetes. By closely mimicking the natural first‑phase insulin release, Afrezza can lower post‑meal glucose excursions effectively while reducing the risk of late‑onset hypoglycemia. However, its use demands careful patient selection (excluding those with lung disease or smoking history), impeccable inhalation technique, and rigorous glucose monitoring to avoid early post‑meal hypoglycemia. When used appropriately, Afrezza provides a valuable needle‑free option for both type 1 and type 2 diabetes, improving patient satisfaction and adherence to prandial insulin therapy. Future research may further clarify its role in special populations and the long‑term safety of pulmonary insulin delivery.

For further reading, see: FDA prescribing information for Afrezza; Clinical trial comparing Afrezza with insulin aspart (Diabetes Care, 2015); and Pharmacokinetic profile of Afrezza in healthy volunteers (J Clin Pharmacol, 2015).